JP Morgan Maintains Overweight on Annexon, Raises Price Target to $15
9/30/2026
Impact: 75
Healthcare
JP Morgan analyst Anupam Rama has maintained an Overweight rating on Annexon (NASDAQ: ANNX) and increased the price target from $14 to $15. This adjustment reflects a positive outlook for the company in the market.
AI summary, not financial advice
Share: